The CAPItello-280 study (NCT05348577) was investigating Truqap in combination with docetaxel and androgen-deprivation therapy (ADT) compared to docetaxel and ADT with placebo in p ...

AstraZeneca's hopes of developing its PD-L1 inhibitor Imfinzi for cervical cancer have been hit by a failed phase 3 trial of the drug alongside chemotherapy as a first-line treatment for women ...

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...

After several years of growing expectation, AstraZeneca’s long-awaited MYSTIC immune-oncology trial has failed to show ... over for Imfinzi in lung cancer: the drug has hit its PFS target ...

AstraZeneca ... HER2-negative breast cancers with certain genetic alterations. In the CAPItello-290 study, which evaluated Truqap in triple-negative breast cancer, it failed to move the needle ...

England’s drug approval body has resisted pressure from pharmaceutical companies to loosen its process for recommending drugs and is pressing instead for the NHS to speed up the rollout of approved ...

AstraZeneca (NASDAQ ... improvement as a first line treatment of metastatic breast cancer, compared to standard care. Enhertu, an antibody drug conjugate, is being jointly developed and ...

A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer has interim clinical data showing it helped patients ...

AstraZeneca (NASDAQ ... their jointly developed antibody-drug conjugate, reached the main goal in a Phase 3 trial in certain patients with early-stage breast cancer as a treatment before surgery.

Sir Pascal Soriot, AstraZeneca’s chief executive ... for terminal breast cancer patients. However, Nice ruled that Enhertu did not offer value for money. The drug is currently not available ...

AstraZeneca has ... was investigating the drug in combination with paclitaxel in patients with locally advanced (inoperable) or metastatic triple-negative breast cancer (TNBC).

AstraZeneca ... cancer charities. The medicine has been found to double the life expectancy for terminal breast cancer patients. However, Nice ruled that Enhertu did not offer value for money. The ...